Our programs include innovative peptides, small molecules and antibody drug conjugates in 3 fields of research

Click a category to discover our solutions

Hallmarks of Cancer

Hallmarks targeted by Debiopharm development programs

  • Prevention of sustained proliferative signaling

    Cancer cells multiply by altering growth-promoting signals and becoming independent of them. We antagonize this process either through hormonal analog therapy or through elimination of cells expressing specific receptors.

  • Re-establish growth suppression

    Oncogene and tumor suppressor analogs could halt cancer growth despite mechanisms bypassing the natural growth-regulating process.

  • Hack non-mutational epigenetic reprogramming

    Epigenetic drugs act mainly targeting the epigenetic mechanisms that regulate gene expression, including methylation and histone modification. Epigenetic changes are reversible, occurring in both natural and diseased states.

  • Boosting natural immune destruction

    Immunotherapies are designed to either amplify the body’s natural immune response (activation immunotherapies) or suppress it (suppressive immunotherapies). Usually, the immune system eliminates cancer cells, but some tumors evade the immune response by disabling some components or recruiting immunosuppressive cells.

  • Outsmart replicative immortality

    Cancer cells can grow exponentially due to their ability to replicate in an unlimited manner without entering senescence or crisis. Through targeted peptide and antibody-based therapy we can trigger programmed cell death.

    Get in touch
  • Halt tumor-promoting inflammation

    Growing tumors generate a state of inflammation that contributes to its development by supplying nutrients and growth factors. Inhibitor of apoptosis proteins (IAPs) hinder cell survival and inflammation through modulation of NF-KB and MAPK pathways.

    Get in touch
  • Combat polymorphic microbiomes

    Microbiomes, particularly gut ones, impact health and disease. Dysbiosis can lead to issues like colon cancer, with certain bacteria affecting DNA replication and repair.

  • De-activating invasion & metastasis

    Inhibiting one of the many proteins involved in epithelial-mesenchymal transition of cancer cells could alleviate metastasis of cancer. Cancer cells may alter shape and attachment, favoring invasion and metastasis.

  • Hindering vasculature

    Anti-angiogenic therapies prevent the tumor from forming new blood vessels for nutrients and waste removal, impairing tumor growth.

  • Exploiting cell senescence

    Inhibiting one of the pathways determining cellular aging and apoptosis, which can be disabled by some cancers, may help induce cell death through alternative pathways.

  • Capitalize on genome instability & synthetic lethality

    DNA instability and mutations enable cancer cell growth and dominance. Inhibiting the tumoral response to DNA damage triggers cell death due to excessive DNA breakage.

    Get in touch
  • Overcome resistance to cell death

    Cancer cells avoid cell death by impairing tumor suppressor function and manipulating apoptotic regulators. Inhibitor of apoptosis proteins (IAPs) promote cell death through caspase modulation.

    Get in touch
  • Impeding dysregulated cellular metabolism

    Blocking the shift of cancer cells to a low-oxygen state or leveraging the cell’s reliance on glucose are interesting ways to prevent cancer from thriving and spreading.

  • Fight phenotypic plasticity

    Interventions that block or reverse dedifferentiation, transdifferentiation or differentiation of stem cells can prevent metastases.


Program Indication Mode of Action
Discovery Preclinical Phase I Phase II Phase III
_ Debio 4326
Central Precocious Puberty – 12M GnRH triptorelin formulation
12M GnRH triptorelin formulation
_ Debio 4126
Acromegaly – Synthetic Somatostatin analogue
Synthetic Somatostatin analogue
_ Debio 0228
Oncology – CAIX-targeted radiotherapy
CAIX-targeted radiotherapy
_ Debio 4228
Oncology – Undisclosed
_ Debio 0432
Oncology – USP1 inhibitor
USP1 inhibitor
_ Debio 4028
Oncology – IAP antagonist
IAP antagonist
_ Debio 0633
Oncology – Undisclosed ADC/Multilink™
Undisclosed ADC/Multilink™
_ Debio 0532
Oncology – Anti-HER3 ADC/ Multilink™
Anti-HER3 ADC/ Multilink™
Repare: Repare Therapeutics
Merck: Merck KGaA

Enabling Technologies

Program Indication Mode of Action
Prototype Preclinical Phase I Phase II Phase III
_ Multilink™
Multidrug linker platform – Cleavable linker for ADC, applicable to different payloads
Cleavable linker for ADC, applicable to different payloads
_ AbYlink™
Diagnostic and therapeutic antibody conjugation technology – Antibody conjugation
Antibody conjugation
Genome: Genome & Company
Ubix: Ubix Therapeutics

Infectious disease

Program Indication Mode of Action
Discovery Preclinical Phase I Phase II Phase III
_ Debio 1455
Inflammatory Bowel Disease – Microbiome remodelling
Microbiome remodelling
_ FibroTrap™ (Debio 1561)
Infectious diseases – Sample prep. Technology
Sample prep. Technology
ODD: Orphan Drug Designation
FT: Fast-Track
QIDP: Qualified Infectious Disease Product
CARB-X grant: CARB-X

Our commercialized products

  • Triptorelin

    Triptorelin is a gonadotropin releasing hormone (GnRH) agonist

  • Oxaliplatin

    A major advance in the history of cancer treatment